Navigation Links
Endo Health Solutions Announces Receipt of Requisite Consents and Expiration of Consent Solicitations Relating to its 7% Senior Notes Due 2019, 7.00% Senior Notes Due 2020 and 7 1/4% Senior Notes Due 2022
Date:11/27/2013

MALVERN, Pa., Nov. 27, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) ("Endo") today announced that, as reported by the tabulation agent, the requisite holders of its senior notes listed below (collectively the "Notes") had consented to the proposed amendments to the indentures governing the Notes (the "Proposed Amendments"), upon the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated November 19, 2013 (the "Statement").

 Series of NotesCUSIPOutstanding Principal AmountConsents ReceivedPercentage7% Senior Notes due 201929264F AG1

$500,000,000

$485,445,000

97.1%7.00% Senior Notes due 202029264F AE6

$400,000,000

$393,065,000

98.3%7¼% Senior Notes due 202229264F AJ5

$400,000,000

$398,145,000

99.5% 

As of 5:00 P.M., New York City time, on November 27, 2013 (the "Expiration Date"), Endo received valid consents in respect of a majority in aggregate principal amount of each series of the outstanding Notes. Accordingly, Endo intends to enter into supplemental indentures, by and among Endo, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, to each of the indentures governing the Notes, reflecting the Proposed Amendments. Subject to the terms and conditions set forth in the Statement, Endo will pay eligible holders who have validly delivered and not revoked consents on or prior to the Expiration Date, a cash payment equal to $2.50 per $1,000 aggregate principal amount of each series of Notes consented (the "Consent Fee").

The Consent Fee will be payable subject to satisfaction or, where possible, waiver of, the Consent Conditions (as defined in the Statement), including the closing of the Transactions (as defined in the Statement). The Proposed Amendments will not become operative until immediately prior to the effective time of the Transactions and shall cease to be operative if the Transactions are not consummated or payment of the Consent Fee is not made.

Persons with questions regarding the consent solicitations should contact the solicitation agents, RBC Capital Markets at (877) 381-2099 (toll free) or (212) 618-7822 (collect) or Deutsche Bank Securities at (855) 287-1922 (toll free) or (212) 250-7527 (collect), or the information, tabulation and paying agent, D.F. King & Co., Inc. at (800) 735-3591 (toll free) or (212) 269-5550 (bankers and brokers).

This announcement is for information purposes only and is neither an offer to sell nor a solicitation of an offer to buy any security. This announcement is also not a solicitation of consents with respect to the Proposed Amendments or any securities. The solicitation of consents is not being made in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such solicitation under applicable state or foreign securities or "blue sky" laws.About Endo Endo Health Solutions Inc. is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services and provide quality products to its customers while improving the lives of patients. Through its operating companies - AMS, Endo Pharmaceuticals, HealthTronics and Qualitest - Endo is dedicated to finding solutions for the unmet needs of patients.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include the following: Endo's intention to solicit consents from the holders of the Notes to the Proposed Amendments. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in Endo's Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause Endo's actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 


'/>"/>
SOURCE Endo Health Solutions Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. BD to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. TCS Named a Global Leader in IDC MarketScape: Worldwide Life Science Sales & Marketing ITO 2013 Vendor Assessment by IDC Health Insights
5. CVS Caremark to Purchase Coram Infusion Business from Apria Healthcare, Expanding Specialty Pharmacy Offering
6. New Agreements and Stock Movements in Healthcare Companies - Research Report on Abbott, Thermo Fisher, Intuitive Surgical, Mindray, and Zeltiq
7. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
8. Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
9. RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
10. Quest Diagnostics To Speak At The Piper Jaffray 25th Annual Healthcare Conference
11. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... , ... The Lung Institute has partnered with the Gulfcoast North ... 6 at their clinic in downtown Tampa. The class is complimentary for the public. ... created a free downloadable 4 Week Smoking Cessation Guide for those who ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, D.P.M., ... with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to be ... Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in treating ...
Breaking Medicine News(10 mins):